We demonstrate the beneficial effect of combination treatment with cytarabine plus the inhibitor of plasmin activation, ε-aminocaproic acid (EACA), in B-ALL, in preclinical models and provide human data supporting the prognostic and therapeutic relevance of interfering with fibrinolysis in human B-ALL. The gene discussed is PLG; the disease is precursor B-cell acute lymphoblastic leukemia.